

Schedule of Events | Appendix 1 Screening and Drug Administration



Phase of trial	Screening			Stu	dy Drug A	Study Drug Administration	ion				
Week		0	2	4	9	æ	10	12	41		
Visit	7	0	~	2	8	4	5	9	7	Ō	TM/DV ²
			General Assessments	Assessm	ents						
Informed Consent	>										
Eligibility criteria	>										
Demographics (age, gender, ethnicity)	>										
Medical history	>										
Rheumatoid arthritis history	>										
Comprehensive physical exam	>	>								>	>
Vital signs	>	5	5	5		>		5		>	>
Randomization		>									
Limited physical exam			>	>		>		>			
Adverse events		>	>	>	>	>	>	>	>	>	>
Concomitant medications	>	>	>	>	>	>	>	>	>	>	>
Telephone assessment of changes since prior visit					>		>		>		

Treatment Modification or Study Discontinuation visit. If treatment modification or intent to discontinue the study is identified during an in-person visit, convert that visit to a Treatment Modification or intent to discontinue the study is identified between in-person visits, then schedule the Treatment Modification or Study Discontinuation Visit for the **Unscheduled Visit**

Vitals monitored per Protocol Section 6.1.1.2.4

next scheduled in-person visit

Page 1 of 8



Schedule of Events | Appendix 1 (Continued) Screening and Drug Administration



Phase of trial	Screening			Stu	Study Drug Administration	dministrati	ion				
Week		0	2	4	9	æ	10	12	14		
Visit	7	0	-	2	3	4	2	9	7	,	TM/DV ²
		Disea	se Spec	Disease Specific Assessments	ssments						
Tender and swollen joint count ⁴	>	>	>	>		>		>		>	>
Patient global health assessment (PaGH)	>	>	>	>		>		>		>	>
Health care provider global health assessment (PrGH) ⁴	>	>	>	>		>		>		>	>
Pain assessment		>								>	>
Health Assessment Questionnaire – Disability Index (HAQ-DI)		>								>	>
PROMIS-29 Profile		>								>	>
		Stu	dy Drug	Study Drug Administration	tration						
VIB4920 or VIB4920 placebo		>	>	>		>		>			



Schedule of Events | Appendix 1 (Continued) Screening and Drug Administration



		TM/DV ²		>	>	>								>	>	>
		,		>	>	>								>	>	>
	14	7														
	12	9		>	>	>										>
ou	10	2														
	œ	4	tral Lab)	>	>	>										>
study Drug Administration	9	က	inical Laboratory Assessments (Central Lab)													
onic	4	2	ssessme	>	>	>										>
	2	-	ratory As			>										>
	0	0	ical Labo	>	>	>										>
Screening		7	Clin	>	>	>	>	>	>	>	>	>	>	>	>	
Fliase of trial	Week	Visit		Hematology (CBC, differential, and platelet count)	Serum chemistry (AST, ALT, bilirubin, alkaline phosphatase, albumin, creatinine)	Inflammatory marker (C-reactive protein)	HIV (RNA or antibody)	Hepatitis B (core antibody, surface antigen)	Hepatitis C (RNA or antibody)	Tuberculosis Testing - QuantiFERON-TB Gold, QuantiFERON-TB Gold Plus, or T-SPOT.TB test ⁵	Anti-phospholipid antibody testing (anti-cardiolipin IgG, IgM, and IgA; antibeta-2-glycoprotein I IgG, IgM, and IgA; Inpus anticoagulant)	SARS-CoV-2 PCR test	Serum pregnancy ⁶	Rheumatoid Factor (RF)	Anti-citrullinated peptide antibodies (ACPA)	STAT urine pregnancy ⁶

not performed within the past 3 months For women with childbearing potential



Schedule of Events | Appendix 1 (Continued) Screening and Drug Administration



Phase of trial	Screening			Stu	Study Drug Administration	dministrat	ion				
Week		0	2	4	9	œ	10	12	14		
Visit	۲	0	-	2	ဗ	4	5	9	7	U ₁	TM/DV ²
		Me	chanisti	Mechanistic Assessments	ments						
Plasma PK pre-infusion assays ⁷		>	>	>		>		>			
Serum PK pre-infusion assays ⁷		>	>	>		>		>			
Plasma PK post-infusion ⁷		>						>			
Plasma anti-drug antibody and sCD40L Assays ⁸		>	>	>		>		>			
PBMCs ⁸		>		>				>			>
Serum ⁸		>		>				>			>
Whole blood RNA ⁸		>		>				>			>
Whole blood DNA ⁸		>		>				>			>
		and all all and all and all all and all all and all all and all all all all all all all all all al									

7 Plasma and serum samples for PK collected pre-infusion and within 15 min +/- 5 min minutes post-infusion 8 Collected prior to infusion



Schedule of Events | Appendix 2 Post Drug-Administration With Dense Sample Collection





		U ¹ TM/		>	>		>	>		>	>	>	>	>	>	>
	40	4		>	>		>	>		>	>	>	>	>	>	>
ling	37/38/39	13.1/13.2/ 13.3												>		
Samp	36	13			>	>	>	>		>	>	>		>		
h Dense	33/34/35	12.1/12.2/ 12.3												>		
n wit	32	12			>	>	>	>		>	>	>		>		
Post-Administration Observation with Dense Sampling	29/30/31	11.1/11.2/	10						ents					>		
on Ok	28	7	nents		>	>	>	>	essm	>	>	>		>		
inistrati	25/26/27	10.1/10.2/	General Assessments						Disease Specific Assessments					>		
-Adm	24	10	enera		>	>	>	>	e Spe	>	>	>		>		
Post	21/22/23	9.1/9.2/ 9.3	Ğ						Diseas					>		
	20	6			>	>	>	>		>	>	>		>		
	17/18/19	8.1/8.2/ 8.3												>		
	16	œ		>	>		>	>		>	>	>	>	>	>	>
Phase of Trial	Week	Visit		Comprehensive physical exam	Vital signs	Limited physical exam	Adverse events	Concomitant medications		Tender and swollen joint count	Patient global health assessment (PaGH)	Health care provider global health assessment (PrGH) ³	Pain assessment	RAPID3 assessment (for dense sampling collection)	Health Assessment Questionnaire Disability Index (HAQ-DI)	PROMIS-29 Profile

Study Discontinuation visit. If treatment modification or intent to discontinue the study is identified between in-person visits, then schedule the Treatment Modification or Study Discontinuation Visit for the next Treatment Modification or Study Discontinuation visit. If treatment modification or intent to discontinue the study is identified during an in person visit, convert that visit to a Treatment Modification Visit or scheduled in-person visit

Assessed by blinded evaluator



Schedule of Events | Appendix 2 (Continued) Post Drug-Administration With Dense Sample Collection



Phase of Trial				Pos	t-Adn	Post-Administration Observation with Dense Sampling	on Ok	servatio	n with	Dense :	Samp	ling			
Week	16	17/18/19	20	21/22/23	24	25/26/27	28	29/30/31	32	33/34/35	36	37/38/39	40		
Visit	ω	8.1/8.2/ 8.3	6	9.1/9.2/ 9.3	10	10.1/10.2/ 10.3	1	11.1/11.2/	12	12.1/12.2/ 12.3	13	13.1/13.2/ 13.3	14	Ĺ	TM/ DV ²
			Clinic	al Labor	atory	Clinical Laboratory Assessments (Central Lab)	ents (Central L	ab)						
Hematology (CBC, differential, and platelet count)	>				>				>				>	>	>
Serum chemistry (AST, ALT, bilirubin, alkaline phosphatase, albumin, creatinine)	>				>				>				>	>	>
Inflammatory marker (C-reactive protein)	>		>		>		>		>		>		>	>	>
Rheumatoid Factor (RF)	>												>	>	>
Anti-citrullinated peptide antibodies (ACPA)	>												>	>	>
				Med	hanis	Mechanistic Assessments	semer	ıts							
Plasma PK Assay	>		>		>		>		>		>		>		
Serum PK Assay	>		>		>		>		>		>		>		
Plasma ADA and sCD40L Assays	>		>		>		>		>		>		>		
PBMCs	>				>				>				>		>
Serum	>				>				>				>		>
Whole blood RNA	>				>				>				>		>
Whole blood RNA-microcontainer (clinic collection)	>														
Whole blood RNA-microcontainer (home collection for dense sampling collection)	>	>	>	>	>	>	>	>	>	>	>	>	>		
Whole blood DNA	>				>				>				>		>





Schedule of Events | Appendix 3 Post Drug-Administration Without Dense Sample Collection

Phase of trial		Post-	-Admini	stration	Observ	ation			
Week	16	20	24	28	32	36	40		
Visit	8	9	10	11	12	13	14	U	TM/DV
	G	eneral <i>A</i>	Assessm	ents					
Comprehensive physical exam	~						~	~	~
Vital signs	~	~	~	~	~	~	~	~	~
Limited physical exam		~	~	~	~	~			
Adverse events	~	~	~	~	~	~	~	~	~
Concomitant medications	~	~	~	~	~	~	~	~	~
	Disea	se Spec	ific Asse	essment	S				
Tender and swollen joint count ¹	~	~	~	~	~	~	~	~	~
Patient global health assessment (PaGH)	~	~	~	~	~	~	~	~	~
Health care provider global health assessment (PrGH) ¹	~	•	~	~	~	•	~	~	~
Pain assessment	~						~	~	~
Health Assessment Questionnaire – Disability Index (HAQ-DI)	~						•	~	~
PROMIS-29 Profile	~						~	~	~
Clinic	al Labor	atory As	ssessme	ents (Cei	ntral Lab	o)			
Hematology (CBC, differential, and platelet count)	~		~		~		~	~	~
Serum chemistry (AST, ALT, bilirubin, alkaline phosphatase, albumin, creatinine)	~		~		~		~	~	~
Inflammatory marker (C-reactive protein)	~	~	~	~	~	~	~	~	~
Rheumatoid Factor (RF)	~						~	~	~
Anti-citrullinated peptide antibodies (ACPA)	~						~	~	~
	Med	chanistic	c Assess	sments					
Plasma PK Assays	~	~	~	~	~	~	~		
Serum PK Assays	~	~	~	~	~	~	~		
Plasma ADA and sCD40L Assays	~	~	~	~	~	~	~		
PBMCs	~		~		~		~		~
Serum	~		*		~		~		*
Whole blood RNA	~		•		•		•		•
	-		•		-		-		-

¹ Assessed by blinded evaluator



Schedule of Events | Appendix 4 Alternate Monitoring



Phase of trial			Alte	ernate l	Monito	ring				
Week of Study	2	4	8	12	16	24	32	40		
Visit	M1	M2	М3	M4	M5	М6	M7	M8	U ¹	DV ²
		Genera	l Asses	sments						
Vital signs	~	~	~	~	~	~	~	~	~	~
Limited physical exam	~	~	~	~	~	~	~	~	~	~
Adverse events ³	~	~	~	~	~	~	~	~	~	~
Concomitant medications	~	~	~	~	~	~	~	~	~	~
Clinic	al Lab	oratory	Assess	ments	(Centra	l Lab)				
Hematology (CBC, differential, and platelet count)		~	~	~	~			~	~	~
Serum chemistry (AST, ALT, bilirubin, alkaline phosphatase, albumin, creatinine)		~	~	~	~			~	~	~
Inflammatory marker (C-reactive protein)					~			~	~	~
	Dise	ase Sp	ecific A	ssessm	ents					
Tender and swollen joint count⁴					~			~	~	~
Patient global health assessment (PaGH)					~			~	~	~
Health care provider global health assessment (PrGH)					~			~	~	~
Pain assessment					~			~	~	~

Additional assessments are permitted, if indicated for participant monitoring.

- 1 Unscheduled visit.
- 2 Study Discontinuation visit. If intent to discontinue the study is identified during an in-person visit, convert that visit to a Study Discontinuation visit. If intent to discontinue the study is identified between in-person visits, then schedule the Study Discontinuation Visit for the next scheduled in-person visit.
- 3 Adverse event monitoring will assess grade 2 or higher adverse events that receive medical attention and AESIs.
- 4 Assessed by blinded evaluator